A new player in the beauty and dermatology sector is seeking to revolutionize the treatment of acne with a groundbreaking innovation. Indomo, a start-up founded by experienced players in the beauty industry, aims to make corticosteroid acne injections more accessible to those struggling with cystic and inflammatory acne. Traditionally, these steroid injections have only been administered in dermatology offices, but Indomo’s development, known as the ClearPen, offers an at-home delivery method. This device is poised to provide patients with rapid relief from acne flare-ups, addressing a significant gap in access to dermatologic care.
The ClearPen operates by injecting corticosteroids through a hidden needle, triggered by the press of a button. This convenient, reusable device can be loaded with single-dose cartridges of the steroid, allowing users to self-administer treatment. Although pricing details are still under evaluation, Indomo is committed to ensuring that the ClearPen will be an insurance-reimbursable option, with prescriptions available both through telehealth services and dermatology offices. By simplifying the process and making treatments available at home, Indomo hopes to alleviate the challenges many face when seeking timely dermatological care.
Jack Abraham, Indomo’s founder and also the co-founder of the telehealth platform Hims & Hers, highlights the pressing need for this innovation. He notes that the current shortage of dermatologists in the U.S. can make it difficult for patients to receive timely treatment during acne flare-ups. With this new self-administration option, Indomo is working to address these access hurdles, making effective treatment more readily available.
Support for Indomo’s mission comes from a shifting cultural landscape regarding at-home medical treatments. Cara Davis, the company’s chief operating officer, emphasizes the growing trust in self-administered therapies, as many individuals have been injecting medications at home for years—whether it’s insulin for diabetes or recent hormonal treatments. With these changes, Davis believes that the ClearPen could become an integral part of drug delivery, not only in dermatology but also in managing other medical conditions.
As Indomo moves forward, the company is gearing up to enter the second phase of clinical trials for the ClearPen in the coming year, inching closer to FDA approval. While an exact launch date is still uncertain, the company’s long-term vision involves expanding the ClearPen’s capabilities to address other skin conditions, including keloids and boils. Davis has expressed confidence in the potential of Indomo to reshape the beauty and dermatology landscape, potentially outperforming any existing at-home solutions.
This innovation comes as consumers increasingly seek professional-grade skincare solutions from the comfort of their homes. As evidenced by recent market trends—such as Shark Beauty’s launch of a device aimed at replicating the benefits of a Hydrafacial—there is a growing demand for high-quality, accessible skin treatments. The industry appears ripe for disruption, and Indomo’s ClearPen could very well be at the forefront of this shift, ultimately changing how individuals manage their acne and skin health.